内科理论与实践 ›› 2021, Vol. 16 ›› Issue (05): 366-370.doi: 10.16138/j.1673-6087.2021.05.016
杨洋, 龚艳春(
)
收稿日期:2021-04-07
出版日期:2021-10-20
发布日期:2022-07-25
通讯作者:
龚艳春
E-mail:gyc10543@rjh.com.cn
Received:2021-04-07
Online:2021-10-20
Published:2022-07-25
中图分类号:
杨洋, 龚艳春. 无症状高尿酸血症与心血管疾病和肾脏疾病关系的研究进展[J]. 内科理论与实践, 2021, 16(05): 366-370.
| [1] |
Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic?[J]. Curr Opin Rheumatol, 2020, 32(1): 71-79.
doi: 10.1097/BOR.0000000000000679 URL |
| [2] | Waheed Y, Yang F, Sun D. The role of asymptomatic hyperuricemia in the progression of chronic kidney disease CKD and cardiovascular diseases CVD[EB/J]. Korean J Intern Med, 2020. https://www.researchgate.net/publication/346312158_The_role_of_asymptomatic_hyperuricemia_ in_the_progression_of_chronic_kidney_disease_CKD_and_cardiovascular_diseases_CVD. |
| [3] | Pijak MR. A role for asymptomatic hyper-uricemia in the progression of cardiovascular and renal disease[J]. BMJ, 2020, 110(5 Pt 1): 2390-2397. |
| [4] |
Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review[J]. BMC Musculoskelet Disord, 2015, 16:296.
doi: 10.1186/s12891-015-0762-4 URL |
| [5] |
Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, et al. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats[J]. J Biol Chem, 2019, 294(11): 4272-4281.
doi: 10.1074/jbc.RA118.006158 pmid: 30651350 |
| [6] |
Li H, Qian F, Liu H, et al. Elevated uric acid levels promote vascular smooth muscle cells (VSMC) proliferation via an nod-Like receptor protein 3 (NLRP3)-inflammasome-dependent mechanism[J]. Med Sci Monit, 2019, 25: 8457-8464.
doi: 10.12659/MSM.916667 URL |
| [7] | Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome[J]. Sci Rep, 2017, 739884. |
| [8] |
Yang X, Gu J, Lv H, et al. Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor[J]. Biomed Pharmacother, 2019, 109: 1163-1170.
doi: 10.1016/j.biopha.2018.10.129 URL |
| [9] |
Liang WY, Zhu XY, Zhang JW, et al. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling[J]. Nutr Metab Cardiovasc Dis, 2015, 25(2): 187-194.
doi: 10.1016/j.numecd.2014.08.006 pmid: 25315669 |
| [10] |
Sánchez-Lozada LG. The pathophysiology of uric acid on renal diseases[J]. Contrib Nephrol, 2018, 192: 17-24.
doi: 10.1159/000484274 pmid: 29393088 |
| [11] |
Song M, Li N, Yao Y, et al. Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis[J]. J Cell Mol Med, 2019, 23(8): 4970-4979.
doi: 10.1111/jcmm.14337 URL |
| [12] |
Gancheva R, Kundurdjiev A, Ivanova M, et al. Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography[J]. Rheumatol Int, 2017, 37(1): 121-130.
doi: 10.1007/s00296-016-3556-6 pmid: 27577941 |
| [13] |
Kim SC, Di Carli MF, Garg RK, et al. Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome[J]. BMC Rheumatol, 2018, 2: 17.
doi: 10.1186/s41927-018-0027-6 URL |
| [14] | Choi HY, Kim SH, Choi AR, et al. Hyperuricemia and risk of increased arterial stiffness in healthy women based on health screening in Korean population[J]. PLoS One, 2017, 12(6): e180406. |
| [15] | Yan NW, Numthavaj P, Thakkinstian A. Association between uric acid and arterial stiffness in general adults: a systematic review and meta-analysis[J]. Ramathibodi Med J, 2018. https://www.researchgate.net/publication/333080340_Association_Between_Uric_Acid_and_Arterial_Stiffness_in_General_Adults_A_Systematic_Review_ and_Meta-analysis. |
| [16] |
Moriyama K. Low-density lipoprotein subclasses are associated with serum uric acid levels[J]. Clin Lab, 2018, 64(7): 1137-1144.
doi: 10.7754/Clin.Lab.2018.180108 pmid: 30146836 |
| [17] |
Tayefi M, Hassanian SM, Maftouh M, et al. Relationship between platelet count and platelet width distribution and serum uric acid concentrations in patients with untreated essential hypertension[J]. Biofactors, 2018, 44(6): 532-538.
doi: 10.1002/biof.1453 URL |
| [18] |
Park JS, Kang S, Ahn CW, et al. Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women[J]. Maturitas, 2012, 73(4): 344-348.
doi: 10.1016/j.maturitas.2012.09.009 URL |
| [19] |
Feldman RD. Sex-specific determinants of coronary artery disease and atherosclerotic risk factors: estrogen and beyond[J]. Can J Cardiol, 2020, 36(5): 706-711.
doi: S0828-282X(20)30219-1 pmid: 32389343 |
| [20] |
Tanaka A, Taguchi I, Teragawa H, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial[J]. PLoS Med, 2020, 17(4): e1003095.
doi: 10.1371/journal.pmed.1003095 URL |
| [21] |
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology[J]. Eur Heart J, 2012, 33(14): 1787-1847.
doi: 10.1093/eurheartj/ehs104 pmid: 22611136 |
| [22] |
Wu X, Jian G, Tang Y, et al. Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities[J]. Nutr Metab Cardiovasc Dis, 2020, 30(4): 666-673.
doi: 10.1016/j.numecd.2019.12.008 URL |
| [23] |
Pan JA, Lin H, Wang CQ, et al. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia[J]. Heart Vessels, 2020: 35(10):1446-1453.
doi: 10.1007/s00380-020-01619-8 URL |
| [24] |
Jörgensen G. Serum uric acid concentrations can predict hypertension: a longitudinal population-based epidemiological study[J]. Horm Metab Res, 2017, 49(11): 873-879.
doi: 10.1055/s-0043-119129 URL |
| [25] | Zhang J, Diao B, Lin X, et al. TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid[EB/J]. Biochimie, 2019. https://linkinghub.elsevier.com/retrieve/pii/S0300-9084(19)30127-0. |
| [26] |
Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk[J]. Am J Cardiol, 2004, 94(7): 932-935.
doi: 10.1016/j.amjcard.2004.06.032 URL |
| [27] |
Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity[J]. Hypertension, 2017, 69(2): 339-348.
doi: 10.1161/HYPERTENSIONAHA.116.08240 URL |
| [28] |
Mazza A, Lenti S, Schiavon L, et al. Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population[J]. Biomed Pharmacother, 2017, 86: 590-594.
doi: 10.1016/j.biopha.2016.11.104 URL |
| [29] |
Cicero AF, Salvi P, D’Addato S, et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study[J]. J Hypertens, 2014, 32(1): 57-64.
doi: 10.1097/HJH.0b013e328365b916 URL |
| [30] |
Storhaug HM, Norvik JV, Toft I, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population[J]. BMC Cardiovasc Disord, 2013, 13:115.
doi: 10.1186/1471-2261-13-115 URL |
| [31] |
Tu W, Wu J, Jian G, et al. Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities[J]. Eur J Clin Nutr, 2019, 73(10): 1392-1402.
doi: 10.1038/s41430-019-0405-1 pmid: 30787471 |
| [32] |
Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis[J]. Sci Rep, 2016, 6: 19520.
doi: 10.1038/srep19520 URL |
| [33] |
Gómez M, Vila J, Elosua R, et al. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population[J]. Atherosclerosis, 2014, 232(1): 134-140.
doi: 10.1016/j.atherosclerosis.2013.10.026 URL |
| [34] |
Suarna C, Dean RT, May J, et al. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1616-1624.
doi: 10.1161/01.ATV.15.10.1616 URL |
| [35] |
Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis[J]. Cardiovasc Ther, 2012, 30(4): 217-226.
doi: 10.1111/j.1755-5922.2011.00277.x pmid: 22099531 |
| [36] | Kuwano K, Ikeda H, Oda T, et al. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis[J]. Am J Physiol, 1996, 270(6 Pt 2): H1993-H1999. |
| [37] |
Wu J, Lei G, Wang X, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities[J]. Oncotarget, 2017, 8(46): 80688-80699.
doi: 10.18632/oncotarget.21079 URL |
| [38] |
Rodríguez-Martín S, de Abajo FJ, Gil M, et al. Risk of acute myocardial infarction among new users of allopurinol according to serum urate level[J]. J Clin Med, 2019, 8(12): 2150.
doi: 10.3390/jcm8122150 URL |
| [39] | Miranda-Aquino T, Pérez-Topete SE, González-Padilla C, et al. Asymptomatic hyperuricaemia and coronary artery disease[J]. Reumatol Clin (Engl Ed), 2020, 17(5): 263-267. |
| [40] |
Gaubert M, Marlinge M, Alessandrini M, et al. Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome[J]. Purinergic Signal, 2018, 14(2):191-199.
doi: 10.1007/s11302-018-9604-9 URL |
| [41] |
Jung SW, Kim SM, Kim YG, et al. Uric acid and inflammation in kidney disease[J]. Am J Physiol Renal Physiol, 2020, 318(6): F1327-F1340.
doi: 10.1152/ajprenal.00272.2019 URL |
| [42] |
Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict?[J]. J Nephrol, 2020, 33(4): 715-724.
doi: 10.1007/s40620-020-00702-7 URL |
| [43] |
Hu C, Wu X. Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue[J]. Int Urol Nephrol, 2019, 51(12): 2227-2233.
doi: 10.1007/s11255-019-02256-5 URL |
| [44] |
Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis[J]. Int Urol Nephrol, 2019, 51(6): 1013-1018.
doi: 10.1007/s11255-019-02154-w pmid: 31020628 |
| [45] |
Liu X, Wang H, Ma R, et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5[J]. Clin Exp Nephrol, 2019, 23(3): 362-370.
doi: 10.1007/s10157-018-1652-5 URL |
| [46] |
Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease[J]. N Engl J Med, 2020, 382(26): 2504-2513.
doi: 10.1056/NEJMoa1915833 URL |
| [47] |
Eleftheriadis T, Golphinopoulos S, Pissas G, et al. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial[J]. J Adv Res, 2017, 8(5): 555-560.
doi: 10.1016/j.jare.2017.05.001 pmid: 28748122 |
| [48] |
Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia[J]. Am J Kidney Dis, 2018, 72(6): 798-810.
doi: 10.1053/j.ajkd.2018.06.028 URL |
| [49] | FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout[J]. Arthritis Care Res(Hoboken), 2020, 72(6): 744-760. |
| [50] |
Hisatome I, Li P, Miake J, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease: Japanese guideline on the management of asymptomatic hyperuricemia[J]. Circ J, 2021, 85(2): 130-138.
doi: 10.1253/circj.CJ-20-0406 pmid: 33342914 |
| [1] | 李若谷. 希氏束起搏的临床应用[J]. 内科理论与实践, 2022, 17(05): 360-364. |
| [2] | 汤宝鹏, 张疆华, 郭衍楷. 无导线起搏器临床应用进展[J]. 内科理论与实践, 2022, 17(05): 365-368. |
| [3] | 李歆旎, 马文坤, 高程洁, 高亚洁, 金雪娟, 周翌, 沈成兴, 潘静薇. 不同诊断标准对人群高血压患病率的影响[J]. 内科理论与实践, 2022, 17(04): 273-277. |
| [4] | 桂燕萍, 陈晔芬, 施仲伟, 许燕. 超声心动图右室面积变化分数筛查左心室射血分数降低的心力衰竭患者心脏同步性研究[J]. 诊断学理论与实践, 2022, 21(03): 331-335. |
| [5] | 李倩倩, 辛晓瑜, 汤荟冬, 吴方. 急性脑梗死住院患者脑白质疏松症的发生率及其影响因素分析[J]. 内科理论与实践, 2021, 16(04): 240-245. |
| [6] | 杨扬, 吴琴咪, 冯玉兰, 张蓓, 傅毅. 高血压患者脑血管周围间隙扩大和脑腔隙灶相关影响因素[J]. 诊断学理论与实践, 2021, 20(04): 372-377. |
| [7] | 刘晓丽, 马晓腾. CYP2C19基因型与冠心病精准抗血小板治疗[J]. 内科理论与实践, 2021, 16(03): 161-166. |
| [8] | 盛虹, 章安迪. 慢性心力衰竭住院患者营养风险评估的临床应用研究[J]. 诊断学理论与实践, 2021, 20(02): 178-183. |
| [9] | 吴洁, 冯媛媛, 任妍, 曹久妹. 基于冠状动脉造影检查的高龄老年人群发生冠心病的危险因素调查及相应诊断模型的建立[J]. 诊断学理论与实践, 2021, 20(02): 201-206. |
| [10] | 中国高血压联盟《动态血压监测指南》委员会. 2020中国动态血压监测指南[J]. 诊断学理论与实践, 2021, 20(01): 21-36. |
| [11] | 张中文, 左祥荣, 郑绪辉, 曹权, 李新立, 李艳秀. 3q26 rs12696304基因多态性与中国南方汉族老年人群急性心力衰竭患者一年预后间的关系研究[J]. 诊断学理论与实践, 2020, 19(06): 565-571. |
| [12] | 李宙童, 张炜, 王继光. 家庭血压测量诊断白大衣高血压及隐匿性高血压的准确性研究[J]. 诊断学理论与实践, 2020, 19(05): 487-493. |
| [13] | 王春花, 祁爽, 王敏. 原发性醛固酮增多症合并无痛性心肌梗死一例报告[J]. 诊断学理论与实践, 2020, 19(05): 528-530. |
| [14] | 陈歆, 程艾邦, 许建忠, 李燕, 王继光. 中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453. |
| [15] | 中国高血压联盟. 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
